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Abstract
Objectives To provide direct estimates of risk of cancer after
protracted low doses of ionising radiation and to strengthen the
scientific basis of radiation protection standards for
environmental, occupational, and medical diagnostic exposures.
Design Multinational retrospective cohort study of cancer
mortality.
Setting Cohorts of workers in the nuclear industry in 15
countries.
Participants 407 391 workers individually monitored for
external radiation with a total follow-up of 5.2 million person
years.
Main outcome measurements Estimates of excess relative risks
per sievert (Sv) of radiation dose for mortality from cancers
other than leukaemia and from leukaemia excluding chronic
lymphocytic leukaemia, the main causes of death considered by
radiation protection authorities.
Results The excess relative risk for cancers other than
leukaemia was 0.97 per Sv, 95% confidence interval 0.14 to
1.97. Analyses of causes of death related or unrelated to
smoking indicate that, although confounding by smoking may
be present, it is unlikely to explain all of this increased risk. The
excess relative risk for leukaemia excluding chronic
lymphocytic leukaemia was 1.93 per Sv ( < 0 to 8.47). On the
basis of these estimates, 1-2% of deaths from cancer among
workers in this cohort may be attributable to radiation.
Conclusions These estimates, from the largest study of nuclear
workers ever conducted, are higher than, but statistically
compatible with, the risk estimates used for current radiation
protection standards. The results suggest that there is a small
excess risk of cancer, even at the low doses and dose rates
typically received by nuclear workers in this study.
Introduction
Ionising radiation is one of the most studied and ubiquitous car-
cinogens in our environment. The main basis for radiation pro-
tection recommendations is the study of survivors of the
Japanese atomic bomb (A bomb), a population exposed
primarily at high dose rates.1–3 The primary public health
concern, however, is the protection of people from relatively low
dose, protracted or fractionated exposures such as those received
by the public in the general environment, by patients through
repeated diagnostic procedures,4 and by radiation workers.
The effects of low dose chronic exposure to external
radiation have been directly estimated in several cohorts of
workers in the nuclear industry,3 but the sample size has limited
the precision of these estimates. Analyses of combined cohorts
have improved precision.5–7 Estimates from these analyses, how-
ever, are compatible with a range of possibilities, from a
reduction of risk at low doses to risks higher than those underly-
ing current radiation protection recommendations.
The 15 country study, an international collaborative study of
cancer risk among radiation workers in the nuclear industry, was
carried out to further improve the precision of direct estimates of
risk after protracted low dose exposures and to strengthen the
scientific basis of radiation protection.1 We present risk estimates
for mortality from all cancers, excluding leukaemia, and from
leukaemia excluding chronic lymphocytic leukaemia and
compare them with estimates derived from data on survivors of
the A bomb. We have used the term nuclear industry to refer to
facilities engaged in production of nuclear power, manufacture
of nuclear weapons, enrichment and processing of nuclear fuel,
production of radioisotopes, or reactor or weapons research.
Uranium mining is not included.
Methods
This multinational retrospective cohort study used a common
protocol in 15 countries and collected information on nearly
600 000 workers. Study cohorts were defined from employment
or dosimetric records of participating facilities or, where
available, from centralised national dose registries. The a priori
eligibility criteria for inclusion of cohorts8 were essentially com-
plete and non-selective follow-up for mortality; availability of
individual annual recorded estimates of dose for all monitored
workers; and availability of information on historical monitoring
policies and practices. We included all workers who had been
monitored for external photon (x and ) radiation exposure
through the use of personal dosimeters. Details of country
specific methods are described elsewhere.9
Ascertainment of vital status and cause of death
We established vital status through linkage with national or
regional death registries. In a few countries where this was not
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possible, appropriate records of local authorities were used.
Completeness of follow-up ranged from 87% to nearly 100%.
Vital statistics registries provided cause of death, which was
known for over 90% of workers who died.
Adequacy of dosimetric records
We reconstructed each worker’s dosimetric history using
recorded doses from individual facilities or national dose
registries. A study of errors in recorded doses evaluated the com-
parability of dose estimates across facilities and time and identi-
fied and quantified sources of bias and uncertainties.9 Doses
from higher energy photons (100-3000 keV), which constituted
most of the dose in most cohorts, were judged to have been
measured in a comparable way over time and across facilities.9 10
The adequacy of practices and technology to measure and
record dose from other radiation types (neutrons, internal expo-
sures), however, varied substantially, particularly in earlier years.
We therefore excluded workers with potential for substantial
doses ( ≥ 10% of their whole body dose) from these radiation
types.
Main study population
The main study population was defined as workers who had
been employed in one or more facilities for at least one year
(113 711 workers excluded), who had been monitored for exter-
nal radiation exposure (38 521 workers excluded), and whose
doses resulted predominantly from higher energy photon radia-
tion (39 730 workers with internal contamination and 19 041
with neutron exposures excluded).
Dosimetric errors and derivation of organ doses
The major sources of errors in higher energy photon doses were
dosimetry technology, exposure conditions, and calibration
practices. Errors from these sources were quantified and bias fac-
tors specific to the doses to each organ of interest calculated for
each model of dosimeter used and by type of facility (nuclear
power plants and mixed activities facilities).11 12 Organ doses were
derived by dividing recorded doses by the appropriate organ
dose bias factor. We used doses to the colon and active bone
marrow for analyses of mortality from all cancers excluding leu-
kaemia and from leukaemia, respectively. All doses are expressed
as dose equivalents in sieverts (Sv).
Statistical methods
Analyses were based on a linear relative risk Poisson regression
model, in which the relative risk is of the form 1+Z, where Z is
the cumulative dose equivalent in Sv and  is the excess relative
risk per Sv; 95% likelihood based confidence intervals were cal-
culated. We used 11 a priori categories of dose ( < 5, 5- < 10,
10- < 20, 20- < 50, 50- < 100, 100- < 150, 150- < 200, 200- < 300,
300- < 400, 400- < 500, ≥ 500 mSv). Analyses used only underly-
ing cause of death. Estimates of excess relative risk were stratified
for sex, age, and calendar period (both in five year categories),
facility, duration of employment ( < 10 years, ≥ 10 years), and
socioeconomic status. In the analyses of all cancers we excluded
cohorts for which socioeconomic information was unavailable or
incomplete (Japan, Idaho National Engineering Laboratory
(INEL), Ontario Hydro Canada), but we included them in analy-
ses of leukaemia as the potential for confounding by
socioeconomic status was thought to be less for leukaemia. To
allow for a latent period between exposure and death, doses were
lagged by two years for leukaemia and 10 years for other cancers,
as in other studies of nuclear workers5–7 and assessments of
radiation risk.1 2 Sensitivity analyses were conducted with a range
of different lags. Attributable risks were estimated by multiplying
the excess relative risks by the average dose in the cohort.
We have focused on the main causes of death for which
radiation protection committees have provided risk estimates: all
cancers excluding leukaemia and leukaemia excluding chronic
lymphocytic leukaemia. Chronic lymphocytic leukaemia is
excluded because it is thought to be less readily inducible by ion-
ising radiation than other leukaemias.3 We have also presented
risk estimates for solid cancers (that is, excluding lymphatic and
haematopoietic malignancies) to compare with recent data for A
bomb survivors13 and for all cancers excluding leukaemia, lung,
and pleural cancers (which have the greatest potential for
confounding by smoking, internally incorporated radionuclides,
and other occupational carcinogens). We investigated confound-
ing by smoking by separately analysing solid cancers related or
unrelated to smoking and two groupings of smoking related out-
comes other than cancer (all non-malignant respiratory diseases
and chronic obstructive bronchitis and emphysema).
Analysis of data from survivors of A bomb
We analysed mortality data from the A bomb survivors for solid
cancer to 199713 and leukaemia to 199014 using similar methods
to provide risk estimates for comparison. Analyses were stratified
for attained age, city, and calendar time and restricted to men
aged 20-60 at exposure, the group most comparable to the
workers.
Results
Overall, 598 068 workers were employed in at least one of 154
facilities. Most facilities were involved in nuclear power
production; the rest specialised in different activities, including
research, waste management, and production of fuel, isotopes,
and weapons. The main study population comprised 407 391
workers (table 1). A total of 24 158 (5.9%) people were known to
have died during the study period: 6519 from cancers other than
leukaemia and 196 from leukaemia excluding chronic
lymphocytic leukaemia. The total duration of follow-up was
5 192 710 person years and the total collective recorded dose
was 7892 Sv. Most workers in the study were men (90%), and
men received 98% of the collective dose. The overall average
cumulative recorded dose was 19.4 mSv. The distribution of
recorded doses was skewed (fig 1). Ninety per cent of workers
received cumulative doses < 50 mSv and less than 0.1% received
cumulative doses > 500 mSv.
For all cancers excluding leukaemia, the excess relative risk
was 0.97 per Sv and was significantly different from zero (95%
confidence interval 0.14 to 1.97) (table 2). This estimate
corresponds to a relative risk of 1.10 for a radiation dose of 100
mSv. For solid cancers, the excess relative risk was 0.87 (0.03 to
1.88), higher than but statistically compatible with the estimate
for A bomb survivors (0.32 per Sv). The excess relative risk for
leukaemia excluding chronic lymphocytic leukaemia was 1.93
per Sv ( < 0 to 8.47), which gives a relative risk of 1.19 for a dose
of 100 mSv. This estimate is between the linear and linear quad-
ratic extrapolations from data on A bomb survivors (table 2).
Table 3 assesses the possible confounding effect of smoking.
Excess relative risks ranged between 0.59 per Sv ( − 0.29 to 1.70)
for all cancers excluding leukaemia and lung and pleural cancer,
and 0.91 per Sv ( − 0.11 to 2.21) for smoking related cancers.
The increased risk for smoking related cancers was mainly
due to an increased risk of lung cancer (1.86 per Sv, 0.26 to 4.01).
Other smoking related cancers showed little evidence of an
increased risk (0.21 per Sv, < 0 to 2.01). Risk estimates for mor-
tality from non-malignant respiratory diseases and from chronic
obstructive bronchitis and emphysema were raised but not
Papers
page 2 of 6 BMJ Online First bmj.com
significantly different from zero (excess relative risk per Sv 1.16,
− 0.53 to 3.84, and 2.12, − 0.57 to 7.46, respectively).
Discussion
Results from our study show that an excess risk of cancer exists,
albeit small, even at the low doses and dose rates typically
received by nuclear workers in this study. The 15 country study
allowed the compilation of the largest body of direct evidence to
date concerning the effects of low dose chronic exposure to ion-
ising radiation. Our risk estimates mainly reflect risks in men, as
there were few exposed women in the cohort.
Dosimetric measurement errors
Reliable estimates of dose were systematically available only for
external exposure to higher energy photons so our results are
restricted to workers exposed mainly to these radiation types. A
detailed study of historical practices and technology allowed us
to identify and quantify the major sources of errors. Analyses
were based on organ dose estimates, which we adjusted to
account for the main sources of systematic errors.
All cancer excluding leukaemia
We found a significantly increased risk for all cancers (excluding
leukaemia). The central risk estimate was higher than the linear
extrapolation from the A bomb survivors. It is unlikely that this
could be due to ascertainment bias, with physicians being more
likely to list cancer as the underlying cause of death for workers
with higher exposures, as the excess relative risk for all
non-cancer mortality was weakly positive (0.20, − 0.26 to 0.72).
We could not adjust directly for possible confounding by
variables such as smoking, diet, and occupational exposures as
information was not available. Some of these factors—
particularly smoking16 and diet—are strongly related to socioeco-
nomic status and adjustment for this will have partially
controlled for their effects. Factors such as smoking can
confound the association between radiation dose and risk only if
they are related both to risk of cancer and to dose. Some cohort
studies have found an association between radiation dose and
smoking,17 18 while others have not.19–21
Although the estimated risk for mortality from lung cancer
was particularly high, mortality from smoking related cancers
other than lung cancer showed little evidence of a relation with
dose. Indeed, the central risk estimate for cancers unrelated to
smoking was higher than that for smoking related cancers other
than lung caner, indicating that confounding by smoking is
unlikely to explain all of the relation found between all cancer
risk and radiation dose. On the other hand, the non-significantly
increased risks for mortality from non-malignant smoking
related diseases indicate a possible effect of smoking. The risk
estimates for mortality from all groups of cancers related and
unrelated to smoking, however, are consistently two to three
times higher than, but statistically compatible with, the risk
estimate for solid cancers from the A bomb analyses (table 3).
Taken together, these findings indicate that a confounding effect
Table 1 Cohorts included in the 15 country study
No of
facilities
First year of
operations
Follow-up
period
No of
workers
Person
years
Deaths
Collective
cumulative dose
(Sv)
Average
individual
cumulative dose
(mSv)
All
causes
All cancers
excluding
leukaemia
Leukaemia
excluding CLL
Australia 1 1959 1972-98 877 12 110 56 17 0 5.4 6.1
Belgium 5 1953 1969-94 5 037 77 246 322 87 3 134.2 26.6
Canada 4 1944 1956-94 38 736 473 880 1 204 400 11 754.3 19.5
Finland 3 1960 1971-97 6 782 90 517 317 33 0 53.2 7.8
France CEA-COGEMA 9 1946 1968-94 14 796 224 370 645 218 7 55.6 3.8
France EDF 22 1956 1968-94 21 510 241 391 371 113 4 340.2 15.8
Hungary 1 1982 1985-98 3 322 40 557 104 39 1 17.0 5.1
Japan 33* 1957 1986-92 83 740 385 521 1 091 413 19 1526.7 18.2
Korea (south) 4 1977 1992-97 7 892 36 227 58 21 0 122.3 15.5
Lithuania 1 1984 1984-2000 4 429 38 458 102 24 1 180.2 40.7
Slovak Republic 1 1973 1973-93 1 590 15 997 35 10 0 29.9 18.8
Spain 10 1968 1970-96 3 633 46 358 68 25 0 92.7 25.5
Sweden 6 1954 1954-96 16 347 220 501 669 190 4 291.8 17.9
Switzerland 4 1957 1969-95 1 785 22 051 66 24 0 111.2 62.3
UK 32 1946 1955-92 87 322 1 370 101 7 983 2201 54 1810.1 20.7
US Hanford 1 1944 1944-86 29 332 678 833 5 564 1279 35 695.4 23.7
US INEL 1 1949 1960-96 25 570 505 236 3 491 886 26 254.6 10.0
US NPP 15 1960 1979-97 49 346 576 682 983 314 19 1336.0 27.1
US ORNL 1 1943 1943-84 5 345 136 673 1 029 225 12 81.1 15.2
Total 154 — — 407 391 5 192 710 24 158 6519 196 7892.0 19.4
CEA-COGEMA=Commissariat à l’Energie Atomique-Compagnie Générale des Matières Nucléaires; EDF=Electricité de France; NPP=nuclear power plants; INEL=Idaho National Engineering
Laboratory; ORNL=Oak Ridge National Laboratory; CLL=chronic lymphocytic leukaemia.
*No information available to allow separation of different facilities.
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Fig 1 Distribution of cumulative radiation doses among workers included in the
analyses
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by smoking may be partly, but not entirely, responsible for the
estimated increased risk for mortality from all cancers other than
leukaemia.
The findings for all cancers excluding leukaemia were not
greatly influenced by data from any one country: formal tests for
heterogeneity provided no evidence for differences in risk
between countries, cohorts, or groups of facilities (P > 0.20). Fig-
ure 2 shows the excess relative risk per Sv in the larger cohorts
( > 100 cancer deaths); the risk estimate for Canada is the largest.
Analyses excluding one cohort or country at a time produced
excess relative risks per Sv ranging from 0.58 (excluding
Canada) to 1.25 (excluding the UK), all consistently higher than,
but compatible with, the estimate from A bomb analyses. Only
when we excluded Canada was the excess relative risk no longer
significantly different from zero (0.58, − 0.22 to 1.55).
Sensitivity analyses of different lag periods showed that both
the risk estimates and their uncertainties increased with increas-
ing lag. The excess relative risk per Sv ranges from 0.76 (0.07 to
1.59) with a lag of five years to 1.68 (0.22 to 3.48) with a lag of 20
years. The estimates are all statistically compatible with the linear
extrapolation from the A bomb survivors.
Leukaemia excluding chronic lymphocytic leukaemia
Although our estimate of risk of leukaemia is not significantly
different from zero, it is similar to estimates from previous large
scale studies of nuclear workers.5 7 Furthermore, it is intermedi-
ate between estimates obtained by fitting a linear and a linear
quadratic dose-response model to data on men exposed to the A
bomb at age 20-60. The excess relative risk per Sv shows only a
small increase with increasing lag periods, from 1.93 ( < 0 to
8.47) with a lag of two years to 2.53 ( < 0 to 10.45) with a lag of
10 years.
The preferred model for the A bomb data includes an effect
of time since exposure.14 Patterns of risk of cancer after low dose
protracted exposures are, however, not necessarily the same as
those observed in A bomb studies. Indeed, the data for nuclear
workers did not show evidence of a time since exposure effect
(not shown).
Our results are not independent of previous combined
analyses.5 7 Analyses excluding workers from these earlier
cohorts, however, yielded similar conclusions.
Implications for radiation protection
The general practice in radiation protection is to estimate risks
for protracted exposures to low doses by extrapolating from
situations of acute exposure to high doses. For this, a linear dose
response model with no threshold is assumed and risk estimates
are divided by two to allow for the assumed reduced
carcinogenicity of exposures received at low dose rates.2 For leu-
kaemia, this is similar to using the linear term of a linear
quadratic model. The central risk estimate for leukaemia from
this study (and from previous studies of nuclear workers) would
support this practice. The confidence interval is wide, however,
and findings are also compatible with no reduction, as well as
with greater reductions of risk at low doses.
For mortality from all cancers excluding leukaemia, the cen-
tral risk estimates are two to three times higher than the linear
extrapolation from the A bomb survivors. The confidence inter-
vals are wide, however, and findings are statistically compatible
with the current bases for radiation protection standards.
Current recommendations form the International Commis-
sion on Radiological Protection (ICRP) are to limit occupational
Table 2 Estimates of excess relative risk per Sv (95% confidence interval) for all cancers excluding leukaemia, solid cancers, and leukaemia excluding
chronic lymphocytic leukaemia, for nuclear workers and survivors of A bomb in Japan*
15 country study Atomic bomb survivors (men exposed at age 20-60)
No of cancers Risk No of cancers Risk†
All cancers excluding leukaemia 5024 0.97 (0.14 to 1.97)
Solid cancers 4770 0.87 (0.03 to 1.88) 3246 0.32‡ (0.01 to 0.50)
Leukaemia excluding CLL:
Linear model 196 1.93 (<0§ to 8.47) 83 3.15¶ (1.58 to 5.67)
Linear quadratic model 1.54** (−1.14 to 5.33)
CLL=chronic lymphocytic leukaemia.
*Colon dose used for all cancers and solid cancer analyses, bone marrow dose for leukaemia.
†Note that because analyses were restricted to men aged 20-60 at exposure the confidence intervals are much wider than those presented by other investigators13 14 and are based on the full
cohort.
‡Analyses carried out at IARC with excess relative risk model that allows for age at exposure modification, adjusted for attained age, calendar period, and city. Estimate for men exposed at age
35.
§Estimate on boundary of parameter space.
¶Analyses carried out at IARC with constant excess relative risk model, adjusted for attained age, calendar period, and city.
**Analyses carried out at IARC—linear term of linear quadratic model—preferred model for describing leukaemia mortality in analyses of data on A bomb survivors.14
Table 3 Estimates of excess relative risk per Sv (95% confidence intervals)
for specific causes of death
Cause of death* No of deaths Risk
All cancers excluding leukaemia 5024 0.97 (0.14 to 1.97)
All cancers excluding
leukaemia, lung and pleural
cancers
3528 0.59 (−0.29 to 1.70)
Solid cancers 4770 0.87 (0.03 to 1.88)
Smoking related solid cancers† 2737 0.91 (−0.11 to 2.21)
Solid cancers unrelated to
smoking
2033 0.62 (−0.51 to 2.20)
*Colon dose used for all cancers excluding leukaemia; all cancers excluding leukaemia, lung
and pleural cancers; solid cancers; and solid cancers unrelated to smoking. Lung dose used
for smoking related solid cancers.
†Those cancers identified as having sufficient evidence for being caused by smoking in recent
IARC monograph15: cancers of lung, oral cavity, nasopharynx, oropharynx, and hypopharynx,
nasal cavity and paranasal sinuses, larynx, esophagus, stomach, pancreas, liver, kidney (body
and pelvis), ureter, urinary bladder, and uterine cervix. Category of cancers unrelated to
smoking comprised all other solid cancers.
Canada
Sweden
UK - all
USA - Hanford
USA - NPP
USA - ORNL
All combined
-2 0 2 4 6 8 10
Cohorts
Excess relative risk/Sv
Fig 2 Excess relative risks per Sv for all cancer excluding leukaemia in cohorts
with more than 100 deaths (NPP=nuclear power plants, ORNL=Oak Ridge
National Laboratory)
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doses to 100 mSv over five years (not to exceed 50 mSv in any
one year) and doses to the public to 1 mSv per year.2 Our
estimates suggest that a cumulative exposure of 100 mSv would
lead to a 9.7% (1.4 to 19.7%) increased mortality from all cancers
excluding leukaemia and a 5.9% ( − 2.9 to 17.0%) increased mor-
tality from all cancers excluding leukaemia, lung, and pleura
compared with background rates. The corresponding figure is
19% ( < 0 to 84.7%) for mortality from leukaemia excluding
chronic lymphocytic leukaemia. Less than 5% of workers in this
study received cumulative doses of the order of 100 mSv over
their entire career, however, and most of these doses were
received in the early years of the nuclear industry, when protec-
tion standards were less stringent than today. Overall, on the
basis of our central risk estimates, we estimate that 1-2% of
deaths from cancer (including leukaemia) among workers in this
cohort may be attributable to radiation.
Conclusions
We have provided radiation risk estimates from the largest study
of nuclear industry workers conducted so far. These estimates
are higher than, but statistically compatible with, the current
bases for radiation protection standards. The confidence
intervals range from values lower than those derived by linear
extrapolation from data from A bomb survivors up to values that
exceed this extrapolation by a factor of six for cancers other than
leukaemia and nearly three for leukaemia. These results suggest
that an excess risk of cancer exists, albeit small, even at the low
doses and dose rates typically received by nuclear workers in this
study.
We are grateful to Richard Doll, Jacques Estève, and Bruce Armstrong who
helped to start this study; to the late Len Salmon who inspired the study of
errors in doses; to past members of the dosimetry and epidemiology
subcommittees (William Murray, Robert Rinsky) and of the international
study group (the late E Gubéran, Y Hosoda, T Iwasaki, G Kendall, M
Murata, T Rytomaa); to everyone in the participating countries who worked
in the collection and validation of the data used in the study; and to the rep-
resentatives and staff of the nuclear facilities included in the study for their
open collaboration.This report uses data obtained from the Radiation
Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan.
RERF is a private, non-profit foundation funded by the Japanese Ministry of
Health, Labour and Welfare and the US Department of Energy through the
National Academy of Sciences. The conclusions in this report are those of
the authors and do not necessarily reflect the scientific judgment of RERF
or its funding agencies.
Contributors: ECa designed and coordinated the international study, took
part in data analysis, interpretation, and writing of the paper, and is guaran-
tor. MV took part in data analysis, interpretation, and writing of the paper
for the international study. As members of the epidemiology subcommittee
MB, EG, MH, CHi, GH, JKa, CM, MS-B, and TY contributed to the concep-
tion and design, the development of the analytical strategy, and the analysis
and interpretation of the data of the international study. They also contrib-
uted to the collection and validation of data in their own countries. As
members of the dosimetry subcommittee FB, GC, JJF, CHa, BH, MMarshall,
IT-C, and DU developed the protocol for the study of errors in doses,
collected data on dosimetry practices, and participated in the review and
analysis of dosimetry questionnaires and in the identification and quantifi-
cation of errors in photon dose estimates. The study of errors in doses was
the topic of IT-C’s PhD dissertation and postdoctoral fellowship, and she
was involved in all of the steps of data acquisition, validation, and analysis
and in the planning and conducting of the dosimetry experiments and the
derivation of the dosimetric bias conversion factors. The other members of
the international study group (YOA, PA, AA, JMB, JBS, AB, PD, ADS, ME,
HE, GE, LMG, GG, RH, KH, HH, AK, JKu, HM, AMa, IT, MU) took part in
the design of the common protocol and were responsible for implementa-
tion of the core protocol and the collection and validation of data in their
countries. FR-A, AR, MT-L, and KV coordinated data collection or
otherwise contributed to data acquisition, analysis, and interpretation of
data at the national level in their countries. EA, ECo, AMo, and HT were
responsible for management of the international database and for data
validation and analysis at IARC. MMartuzzi and DBR assisted in validation
of the data at the international level, implementation of the protocol at the
national level, and provided assistance to national collaborators through
contacts and site visits. MSP assisted in the validation and analysis of the
international dataset. All authors critically reviewed earlier drafts for impor-
tant intellectual content and approved the final version of the paper.
Funding: European Union (contracts F13P-CT930066, F14P-CT96-0062,
FIGH-CT1999-20001); US Centers for Disease Control (Co-operative
agreement U50/CCU011778); Canadian Nuclear Safety Commission;
Japanese Institute for Radiation Epidemiology, Australian Nuclear Science
and Technology Organisation; Nuclear Research Center (SCKCEN),
Belgium; Health Canada and Statistics Canada; La Ligue Nationale contre
le Cancer, France; La Compagnie Générale des Matière Nucléaire, France;
Electricité de France; Ministry of Education, Culture, Sports, Science and
Technology in Japan; Ministry of Science and Technology (MOST) in
Korea; Spanish Nuclear Safety Council; US Department of Energy. These
sponsors had no role in study design, data collection, analysis, or interpreta-
tion. IT-C received funding from the Association pour la Recherche contre
le Cancer (ARC, France); MSP and DBR were the recipients, respectively, of
an IARC postdoctoral fellowship and of an ORAU fellowship during their
stay at IARC.
Competing interests: C Hacker, B Heinmiller, H Hyvonen, M Marshall, A
Rogel, J Bernar Solano, M Eklöf, and K Holan are (or have been in the past
five years) employees of the nuclear industry or have links to the nuclear
industry in their country. They were appointed to the international study
group and or the dosimetry subcommittee as experts because of their criti-
cal knowledge and experience in historical radiation protection practices
and dosimetry. None of them had influence on decisions concerning analy-
sis of the results.
Ethical approval: The study was approved by the IARC ethical review com-
mittee and by the relevant ethical committees of the participating countries.
1 BEIR V. Committee on the Biological Effects of Ionizing Radiation. The effects on popu-
lations of exposure to low levels of ionizing radiation. Washington, DC: National Academy
of Sciences, 1990.
2 International Commission on Radiological Protection ICRP. Recommendations of the
international commission on radiological protection. Oxford: Pergamon Press, 1991. (ICRP
publication 60.)
3 United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR).
Sources and effects of ionizing radiation. New York: United Nations, 2000.
4 Berrington de González A, Darby S. Risk of cancer from diagnostic X-rays: estimates
for the UK and 14 other countries. Lancet 2004;363:345-51.
5 IARC Study Group on Cancer Risk among Nuclear Industry Workers. Direct estimates
of cancer mortality due to low doses of ionising radiation: an international study. Lan-
cet 1994;344:1039-43.
6 Cardis E, Gilbert ES, Carpenter L, Howe G, Kato I, Armstrong BK, et al. Effects of low
doses and low dose rates of external ionizing radiation: cancer mortality among
nuclear industry workers in three countries. Radiat Res 1995;142:117-32.
7 Muirhead CR, Goodill AA, Haylock RGE, Vokes J, Little MP, Jackson DA, et al. Occupa-
tional radiation exposure and mortality: second analysis of the national registry for
radiation workers. J Radiol Prot 1999;19:3-26.
8 Cardis E, Estève J. International collaborative study of cancer risk among nuclear industry
workers. I—Report of the feasibility study. II—Protocol report 92/001. Lyons: International
Agency for Research on Cancer, 1992.
9 Cardis E, Martuzzi M, Amoros E. International collaborative study of cancer risk among
nuclear industry workers. III—Procedures document, rev 1. Lyons: International Agency for
Research on Cancer, 1997. (97/002.)
10 Fix JJ, Salmon L, Cowper G, Cardis E. A retrospective evaluation of the dosimetry
employed in an international combined epidemiological study. Radiat Protect Dosimetry
1997;74:39-53.
11 Thierry-Chef I, Pernicka F, Marshall M, Cardis E, Andreo P. Study of a selection of 10
historical types of dosemeter: variation of the response to Hp(10) with photon energy
and geometry of exposure. Radiat Prot Dosimetry 2002;102:101-13.
12 Thierry-Chef I, Cardis E, Ciampi A,Delacroix D,Marshall M, Amoros E, et al. A method
to assess predominant energies of exposure in a nuclear research centre—Saclay
(France). Radiat Prot Dosimetry 2001;94:215-25.
13 Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of
atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality:
1950-1997. Radiat Res 2003;160:381-407.
What is already known on this topic
Current radiation protection standards are based mainly on
data from the survivors of the atomic bomb in Japan
The estimation of risks after low dose protracted or
fractionated exposures to ionising radiation is controversial
What this study adds
A small excess risk of cancer exists, even at the low doses
typically received by nuclear industry workers in this study
Papers
BMJ Online First bmj.com page 5 of 6
14 Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of
atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 1996;146:1-
27.
15 International Agency for Research on Cancer. IARC monographs on the evaluation of car-
cinogenic risks to humans. Vol 83. Tobacco smoke and involuntary smoking. Lyons: IARC,
2004.
16 Lee DJ, LeBlanc W, Fleming LE, Gomez-Marin O, Pitman T. Trends in US smoking
rates in occupational groups: the national health interview survey 1987-1994. J Occup
Environ Med 2004;46:538-48.
17 Gribbin MA, Weeks JL, Howe GR. Cancer mortality (1956-1985) amongst male
employees of Atomic Energy of Canada Limited with respect to occupational exposure
to external low linear energy transfer ionizing radiation. Radiat Res 1993;133:375-80.
18 Murata M, Miyake T, Inoue Y, Ohshima S, Kudo S, Yoshimura T, et al. Life-style and
other characteristics of radiation workers at nuclear facilities in Japan: base-line data of
a questionnaire survey. J Epidemiol 2002;12:310-9.
19 Peterson G, Gilbert ES, Buchanan JA, Stevens RG. A case-cohort study of lung cancer
ionizing radiation, and tobacco smoking among males at the Hanford sites. Health Phys
1990;58:3-11.
20 Carpenter L, Fraser P, Booth M, Higgins C, Beral V. Smoking habits and radiation
exposure. J Radiol Protection 1989;9:286-7.
21 Auvinen A, Pukkala E, Hyvönen H, Hakama M, Rytömaa T. Cancer incidence among
Finnish nuclear reactor workers. J Occup Environ Med 2002;44:634-8.
(Accepted 23 May 2005)
doi 10.1136/bmj.38499.599861.E0
International Agency for Research on Cancer, Lyons, France
E Cardis head of radiation group
M Vrijheid scientist
I Thierry-Chef postdoctoral student
E Combalot research assistant
H Tardy research assistant
Institute of Medical Biostatistics, Epidemiology and Informatics, University of
Mainz, Germany
M Blettner professor
Radiation Epidemiology Branch, Division of Epidemiology and Genetics, National
Cancer Institute, Bethesda, MD, USA
E Gilbert expert
University of Tampere, Tampere, Finland
M Hakama research professor
A Auvinen research professor
Institut Gustave-Roussy, Villejuif, France
C Hill epidemiologist
Mailman School of Public Health, Columbia University, New York, USA
G Howe professor of epidemiology
National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW,
Australia
J Kaldor deputy director
Radiation Protection Division, Health Protection Agency, Chilton, Didcot,
Oxfordshire
C R Muirhead group leader epidemiology
Division of Surveillance, Hazard Evaluations and Field Studies, National Institute
for Occupational Safety and Health, Cincinnati, OH, USA
M Schubauer-Berigan senior research epidemiologist, industrywide studies branch
D Utterback chief, health-related energy research branch
Fukuoka Institute of Health and Environmental Sciences, Fukuoka, Japan
T Yoshimura director
Conseiller Médical du CEA, Paris, France
F Bermann medical counsellor
Atomic Energy Commission of Canada, Deep River, ON, Canada
G Cowper consultant to IARC
Pacific Northwest National Laboratory, Richland, WA, USA
J Fix staff scientist
Safety and Radiation Science, Australian Nuclear Science and Technology
Organisation, NSW, Australia
C Hacker health physicist
AECL Radiation Biology and Health Physics Branch, Chalk River Laboratories,
Chalk, ON, Canada
B Heinmiller senior scientist
Twin Trees, Blewbury, Didcot, Oxfordshire
M Marshall consultant to IARC on radiation dosimetry
Department of Preventive Medicine, Seoul National University College of
Medicine, Seoul, Korea
Y-O Ahn professor
Epidemiological Research and Surveillance Unit in Transport, Occupation and
Environment; French National Institute for Transport and Safety Research
(INRETS), Arcueil, France
E Amoros research assistant
Radiation Protection Bureau, Health Canada, Ottawa, Canada
P Ashmore affiliate scientist at the McLaughlin Centre
Department of Preventive Medicine, Cheju National University College of
Medicine, Cheju, Korea
J-M Bae associate professor
AMYS, UNESA, Madrid, Spain
J Bernar Solano head of division of research
Institute of Radioprotection and Nuclear Security, DESTQ/DEAS, Le Vésinet,
France
A Biau director of scientific and technical assessment
Nuclear Research Centre (SCK.CEN), Radiation Protection Division, Mol, Belgium
P Deboodt health physicist
H Engels nuclear inspector
Operational Radiological Protection, Nuclear Safety Council, Spain
A Diez Sacristan inspector
Statens Vattenfallsverk Forsmark, Osthammer, Sweden
M Eklof
Institute for East-European Studies, Uppsala University, Sweden
G Engholm principal administrative officer
Department of Hygiene and Epidemiology, Faculty of Health Care and Social
Work, Trnava University, Trnava, Slovak Republic
G Gulis associate professor
Faculty of Health Sciences, American University of Beirut, Lebanon
R Habib assistant professor
Slovenske Elektrárne, Bratislava, Slovak Republic
K Holan senior adviser
Doseco Ltd, Jyvaskyla, Finland
H Hyvonen managing director
“Frederic Joliot-Curie” National Research Institute for Radiobiology and
Radiohygiene of the “Fodor József” National Centre for Public Health, Budapest,
Hungary
A Kerekes head
I Turai head chief physician
Lithuanian Cancer Registry, Vilnius University Oncology Institute, Vilnius,
Lithuania
J Kurtinaitis chief
Vasternorrland County Council, Department of Research and Development,
Sundsvall, Sweden
H Malker research director
WHO European Centre for Environment and Health, Rome, Italy
M Martuzzi technical officer
Radiation Protection Centre, Vilnius, Lithuania
A Mastauskas head
Serono International SA, Geneva, Switzerland
A Monnet senior statistical programmer
Physics and Biology Section, Radiation Protection Division, Federal Office of
Public Health, Bern, Switzerland
M Moser chief
School of Clinical Medical Sciences, University of Newcastle upon Tyne, Newcastle
upon Tyne
M S Pearce senior research associate
Department of Epidemiology, School of Public Health, Chapel Hill, NC, USA
D B Richardson assistant professor
Department of Preventive Medicine and Public Health, School of Medicine,
University Autonoma de Madrid, Spain
F Rodriguez-Artalejo professor of preventive medicine and public health
Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear
Safety, Fontenay-aux-Roses, France
A Rogel epidemiologist
M Telle-Lamberton epidemiologist
Medical Inspectorate of Factories, Geneva, Switzerland
M Usel research assistant
Institute of Public Health, Semmelweis University, Budapest, Hungary
K Veress lecturer
Correspondence to: E Cardis cardis@iarc.fr
Papers
page 6 of 6 BMJ Online First bmj.com
